

Company Registration Number 08326993

MICROSKIN PLC
FINANCIAL STATEMENTS
30 JUNE 2016

MICROSKIN PLC

CONTENTS LIST

FOR THE YEAR ENDED 30 JUNE 2016

Contents	Page
Company Directory	1
Strategic Report	2
Directors' Report	6
Independent Audit Report	11
Consolidated Statement of Profit or Loss and Other Comprehensive Income	14
Consolidated Statement of Financial Position	15
Consolidated Statement of Changes in Equity	17
Consolidated Statement of Cash Flows	18
Parent Company Statement of Financial Position	19
Parent Company Statement of Changes in Equity	20
Notes to the Financial Statements	21

MICROSKIN PLC

COMPANY DIRECTORY

AS AT 30 JUNE 2016

Directors	B Amor B Lowndes S McTaggart D Merson
Company Secretary	Elemental CoSec Limited
Company registration number	08326993
Registered office	27 Old Gloucester Street London United Kingdom WC1N 3AX
Auditor	KSI (WA) Level 2 35 Outram Street West Perth WA 6005 Australia
Domicile of the company	United Kingdom
Country of incorporation	England and Wales
Legal form of entity	Public Limited Company
Marche Libre Paris Code	MLSKN

MICROSKIN PLC

STRATEGIC REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Your directors present their Strategic Report for Microskin PLC and its controlled entities (hereafter “the Group” or “Microskin”) for the year ended 30 June 2016.

Principal activities

Microskin PLC is a UK registered company listed on the Marche Libre exchange in Paris. The Group's product, Microskin, is a simulated second skin used to visually correct skin conditions resulting from birth, accident or surgery which are permanent and disfiguring. The operating 100% owned subsidiary is Microskin International Pty Ltd which is an Australian proprietary company.

Microskin is manufactured from natural ingredients and is applied directly to the user's own skin. It competes directly against other products in the camouflage cosmetic market; however, its unique properties of long wear time, water and sun resistance, and the ability for the skin to breathe naturally, enables it to be used on both small and large areas of the body for several days after application.

The Group has strong positioning with the medical profession putting Microskin into a unique market category at the top end of the camouflage cosmetics sector. It is also pursuing product applications in the pure cosmetics and sunscreen markets, amongst others.

The Group's intellectual property includes the formula for making the Microskin base product and a software program that enables colour correction of the product for each user, as well as patents for the process.

The Group develops and manufactures Microskin style products, operates its own clinic in Brisbane, has established franchised clinics in New York, Los Angeles, Indonesia, India, Scandinavia, Brazil, Canada, the Middle East and Turkey, and intends to expand the distribution of Microskin into all major global markets through a network of franchise or licensing arrangements with both clinic operators and manufacturing distributors.

No significant change in the nature of these activities occurred during the year.

Principal Risks and Uncertainties

The directors consider the main risk to the business is a potential lack of capital to fund the following:

- Aggressive business development to increase the rollout of clinics around the world.
- Develop “over the counter” product distribution opportunities.
- Product development to enhance our competitive advantage in the camouflage cosmetic market.
- Develop other applications of Microskin, such as sunscreen.

As the Group expands its operations to a variety of international locations, the directors are also mindful of the Group's exposure to foreign exchange risk. At present, clinic license fees represent a big percentage of the revenue for the Group and are fixed in Australian dollars, therefore not subject to exchange risk. Clinic royalty payments are paid as a percentage of revenue generated in the clinic. The funds are sent to us as Australian dollars and will fluctuate with exchange variation. The directors will give consideration to hedging contracts when the royalty stream is of sufficient size and regularity to justify it.

Operating Results

The loss of the Group after providing for income tax amounted to \$449,626.

While we have been successful in signing license agreements in regions that represent enormous potential for us e.g. India, the Middle East and Brazil, extensive delays in receiving approvals to supply these jurisdictions continues to impact on results.

MICROSKIN PLC

STRATEGIC REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Financial Position

At 30 June 2016, the Group's Statement of Financial Position shows a net asset position of \$18,672,072.

Review of Operations

We are about to commence retail distribution in the US, India and Turkey through our online shopping site, utilizing our Colour Match app and the development of a dermatologist affiliate program.

With the Colour Match app, we can now help anyone, regardless of location, access our second skin products. Once the app finds a skin colour match, the user can order second skin products directly through Microskin's online store.

Determining skin color is a complex process because living skin has multiple layers with varying reflective and translucent properties that change how a skin color is observed depending on the light source. For medical applications, skin color is normally determined in a clinic by trained personnel using a special machine, called a spectrophotometer.

While other apps do a simple paint-matching program which serves up a flat, artificial colour, we took advantage of the excellent computing and camera power of today's mobile devices to build a breakthrough app that captures and calculates skin's reflective and translucent characteristics to identify a person's true skin color.

The first app is available through Apple's App Store. The second app is for dermatologists and skin clinics and requires a specialized iPhone clip-on device, which emits a signature light source to provide a comprehensive color match. The specialized device and app is available through Microskin's clinical partner program.

Our clinics have done an excellent job using Microskin's proprietary color correction software to provide clients an individually formulated second skin product. Now that technology and Microskin's superior colour correction system is accessible to everyone through a simple mobile app.

Business Development

Microskin International PLC has entered into an agreement to acquire the international rights to ISOCOL, excluding Australia and New Zealand. The strategic acquisition will benefit Microskin with the planned expansion of its range of specialised '2nd Skin' products into the retail sector in markets such as Australia, New Zealand, the UK, USA, Asia and Europe.

The ISOCOL brand was founded in Australia in 1982 and has become one of Australia's most trusted and iconic brands with the now very familiar Crocodile on the green bottle and the "One bottle, so many uses" slogan easily recognisable. ISOCOL has developed into a brand that is now widely recognised and sold across Australia and New Zealand in all supermarkets and pharmacies. In 2016 ISOCOL International began to expand into wider international markets with established distribution into the UK, Continental Europe and new pipelines into the burgeoning Asian marketplace which has demonstrated a constant hunger for high quality, well established Australian made products.

Microskin's growth strategy is centred in product development and new market growth. As the current range of Microskin products expand there will be expected sales growth in the domestic Australian market and furthermore in much larger northern hemisphere markets. In support of this focus, Microskin has identified the following target areas for growth:

MICROSKIN PLC

STRATEGIC REPORT

FOR THE YEAR ENDED 30 JUNE 2016

- Expand product range to encompass more suitable products for the retail environment
- Expansion of global distribution capabilities • Greater engagement of current clinic and customer base activities
- Expanding Microskin's online sales and marketing activities

As part of the acquisition, the resources and expertise in overseas market development provided by ISOCOL International will greatly benefit the expansion capabilities of Microskin. A number of strategies ranging in complexity for sales in new markets are currently being developed with the main strategy being to develop new opportunities on a global basis. Microskin are currently developing a portfolio of impressive new products with the focus of capitalising on the momentum of growth seen from ISOCOL International's current expansion into the UK and European markets and opening sales in markets such as India and Asia, where Microskin can capitalise on its unique skincare applications.

The acquisition of ISOCOL International by Microskin, now promises to expand the distribution of the current range of Microskin products as well as new products currently in development and capitalise on the established distribution channels of ISOCOL. This will generate new opportunities in the retail and pharmacy sector within the UK and Europe, which according to US based research company Statista place the value for Cosmetics and Personal Care market at €100 billion for 2016. Global Markets Director of ISOCOL International David Robinson said, "This is an exciting time for these businesses to merge. The ISOCOL products are being received very well in the new markets we are targeting and we forecast robust sales in coming years. To be able to include the specialised range of current and upcoming Microskin products into the distribution channels we are developing allow us to open more doors and therefore generate greater sales in multiple new markets".

Distribution Capabilities – ISOCOL International partner with UK distributor, Pasante Healthcare. Pasante is a market leading healthcare distributor and export and distribute a range of skin and healthcare products to more than 60 countries. The acquisition of ISOCOL International will now allow Microskin to leverage off this partnership and confidently expand into these international markets with a proven distribution partner.

Product Development

We have commenced TGA certification testing of Microskin as a Sunscreen. We will soon be commencing TGA testing of Microskin for other medical applications.

Listing

Listing on the Marche Libre in Paris provides a platform for raising the necessary capital to fund business and product development initiatives.

Environmental matters

There are no environmental issues arising from the Group's business that might affect the future strategic direction or results of our group.


MICROSKIN PLC
STRATEGIC REPORT
FOR THE YEAR ENDED 30 JUNE 2016

Employees

In line with *Companies Act 2006* requirements, we present the following breakdown of our employee structure:

<i>Role</i>	<i>Number of Men</i>	<i>Number of Women</i>
Directors	4	-
Senior Managers	-	1
Other Employees	2	3

By order of the Board



Barry Amor

Director

2 December 2016

MICROSKIN PLC

DIRECTOR'S REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Your directors present their report on the Group for the financial year ended 30 June 2016.

Directors

The names of each person who has been a director during the period and to the date of this report are:

Barry Amor - Executive Chairman

Barry's 40 year career spans the telecommunications, industrial equipment and information systems sectors. The focus of these skills has been on laying solid foundations for organisations intent on developing and exporting a range of complex products and equipment targeting industrial and commercial applications. Barry has cultivated a solid understanding of the issues associated with building export-oriented businesses that have targeted various south-east Asian countries, the USA and New Zealand.

With a solid background in engineering, Barry began his career in telecommunications, subsequently gaining extensive experience in industrial automation, mining equipment, computer and communications hardware and enterprise software systems. The hands on experience gained founding businesses in several of these sectors has given him the ability to see the broad picture as well as the detailed nuances at work in the entrepreneurial environment. Later in his career he oversaw the foundation of a company which has set a new benchmark for enterprise resource planning (ERP) systems for mid-range organisations. Those systems boast a growing customer base in domestic and international markets. As chief executive charged with driving both product development and market growth, he gained an in-depth understanding of government grants for research and development and exports and the tax concessions appropriate to a company operating at the leading edge of technology development. This venture was preceded by a project in which he restructured and managed the sale of a national business distributing software and hardware. He has also run businesses distributing industrial control equipment, computer components and specialised equipment for application in coal mining and the oil industry.

In the last few years Barry has worked inside the corporate advisory sector, with several years working for Gramercy Venture Advisors. Barry is based in Brisbane, Australia.

Barry Lowndes – Director

Barry Lowndes brings to Microskin a wealth of knowledge and understanding from a management perspective. Prior to a period of full-time involvement with Microskin, Barry was the National Security Manager with the Millers Retail Group which comprises over 600 retail stores and 3,000 staff. It was Barry's responsibility to formulate policies and procedures to reduce a growing shrinkage problem, reduce theft and train employees. Barry oversaw the day-to-day activities of all group leaders, including the implementation of objectives and strategies for its managing directors. Barry's final position at Millers was as the chairman of the newly-formed Millers Shrinkage Board, which provided its shareholders with strategies to improve shrinkage performance. In recent times Barry has given up full-time involvement in the day-to-day affairs of Microskin; however, he retains an active involvement as a director.

David Merson – Director

For 21 years, David Merson was the chief executive officer of Mincom Limited, a company he founded in 1979. During his tenure, Mincom grew to become Australia's largest software developer and exporter with 1,200 staff, annual revenues of \$200 million, and global leadership in a number of software product categories.

MICROSKIN PLC

DIRECTOR'S REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Scott McTaggart – Director

An investor and business consultant with shareholding and directorships in MezurX Pty Ltd (drilling services) and Euclidean Pty Ltd (3D graphics). Scott's career has included being a high school teacher, developing software for Mincom (involved in the divestiture of Petroleum Technology Mincom and the sale of Mincom as a shareholder), working for Paradigm Geophysical, Shell and GeoSource, before becoming an Adjunct Associate Professor at the University of Queensland, where he was also director/CEO of two National Earth Science Infrastructure Companies (ACcESS, AuScope). He has a Bachelor of Applied Science in Geophysics (1st Class Honours).

Information on company secretary

Elemental Company Secretary Limited have served the company in the function of company secretary in the year to 30 June 2016.

Group structure

The Group is controlled from Australia, where all its active operations are controlled. The parent company – Microskin PLC – is the only UK company in the Group, and it does not conduct operations.

Significant changes in state of affairs

In July 2015, the Group issued 5,325,279 shares to the vendors of Mobilespectra Pty Ltd, to settle its acquisition of the Group. This was approved via a shareholders general meeting.

In April and May 2016, shares were issued to London Trade and Finance Limited, as part of a share subscription facility to generate funds for the Group, by on-selling those shares.

Matters or circumstances arising after the end of the year

In November 2016, the Group commenced negotiations to acquire Isocol International Limited, a specialist international distributor and holder of the international rights (outside Australia) to the popular Australian product "Isocol." The Directors expect this acquisition to be completed in December 2016.

Aside from as above disclosed, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Future developments and results

Beyond matters specifically discussed by the Board in the Director's Report and the Strategic Report, likely developments in the operations of the Group and the expected results of those operations in future financial years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the Group.

Research and Development

The Group undertakes a variety of research activities into potential new products and new formulations that could form part of their future offerings to customers. The Group classifies all such spending as research and expenses the costs accordingly.

It is the view of the directors at this stage that the Group is unable to confirm the potential flow of benefits from new products until they arrive to market. Given that, it is not possible to capitalise these expenditures as development.

MICROSKIN PLC

DIRECTOR'S REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Environmental issues

The Group's operations, as a product manufacturer and retailer, have a negligible environmental impact. As such, there is no impact from laws of the Commonwealth or of a state or territory of Australia.

Indemnification and insurance of officers and auditors

No indemnities have been given or insurance premiums paid, during or since the end of the financial period, for any person who is or has been an officer or auditor of Microskin PLC.

Proceedings on behalf of the company

No person has applied for leave of court to bring proceedings on behalf of the company or intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The company was not a party to any such proceedings during the period.

Meetings of directors

During the financial year, 7 meetings of directors (including committees of directors) were held. Attendances by each director during the period were as follows:

	Directors' Meetings	
	Number eligible to attend	Number attended
Barry Amor	7	6
Barry Lowndes	7	3
David Merson	7	5
Scott McTaggart	7	3

Dividend policy

The group does not intend to pay dividends for the foreseeable future. At this stage of the group's life cycle, and profits will be re-invested in the growth and future success of the business.

Financial Instruments

The Group holds a number of financial instruments. Information regarding the Group's financial risk management objectives and policies, including exposure to foreign exchange, price, cashflow, credit and liquidity risks, are presented in Note 26 to these financial statements.

Creditor payment policy

The group adheres to a standard payment policy for commercial creditors, meeting its obligations within the timeframe provided by their suppliers. Non-commercial creditors – typically the directors and their related parties – have deferred payment of bills to assist with the group's liquidity.

MICROSKIN PLC

DIRECTOR'S REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Director's Interests

At the year end date, the directors of the company had the following interests in the shares of the company, through both direct and indirect holdings:

30 June 2016	Balance at beginning of year	Acquired during the year	10:1 Share Split	Balance at end of year
Barry Lowndes	3,721,802	-	33,496,218	37,218,020
Barry Amor	5,764,522	-	51,880,698	57,645,220
Scott McTaggart	165,625	-	1,490,625	1,656,250
David Merson	208,333	-	1,874,997	2,083,330
	9,860,282	-	88,742,538	98,602,820

Remuneration report (audited)

Policy & Practice

The Group operates on a strictly 'capital efficient' approach and therefore directors' remuneration has been based on conservative market matching rates in order to act in the best interest of the Group during the Group's growth phase. At this time, outside of existing shareholdings, there are no performance components included in directors' remuneration. Given the limited size of the Group, no separate remuneration committee has been formed by the board.

Contracts

Directors' remuneration in its various forms was agreed by Board resolution, not formalised by contracts at this stage, and these arrangements will continue until re-visited by either party. Thus, there has been no specification of termination benefits for directors at this time.

Amounts of emoluments and compensation

Director	Remuneration including superannuation	
	<i>Year to 30 June 2016</i>	<i>Period to 30 June 2015</i>
	\$	\$
Barry Lowndes	-	-
Barry Amor ¹	137,400	-
Scott McTaggart	-	-
David Merson	-	-
	137,400	-

End of audited section

MICROSKIN PLC

DIRECTOR'S REPORT

FOR THE YEAR ENDED 30 JUNE 2016

Directors' responsibilities

The Directors are responsible for preparing the Strategic Report and the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year or period. Under that law the Directors have elected to prepare the financial statements in accordance with applicable United Kingdom law and those International Financial Reporting Standards ("IFRS") as adopted by the European Union. Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and of the profit or loss of the Group for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with IFRS as adopted by the European Union;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the Group will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Group's transactions and disclose with reasonable accuracy at any time the financial position of the Group and enable them to ensure that the financial statements comply with the Companies Act 2006 and, as regards the group financial statements, Article 4 of the IAS Regulation. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Group's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

Directors' statement as to disclosure of information to the auditor

The Directors at the date of approval of this report confirm that:

- to the best of their knowledge and belief, there is no relevant audit information of which the Group's auditor is unaware; and
- the Directors have taken all the steps that that might reasonably be expected to have taken as a Director in order to make themselves aware of any relevant audit information and to establish that the Group's auditor is aware of that information.

On behalf of the Board



Barry Amor

Director

2 December 2016

MICROSKIN PLC

INDEPENDENT AUDITORS' REPORT TO THE SHAREHOLDERS

FOR THE YEAR ENDED 30 JUNE 2016

We have audited the financial statements of Microskin PLC on pages 14 to 52 for the year ended 30 June 2016. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union.

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of the directors and auditors

As explained more fully in the Director's Responsibilities Statement on page 10, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all financial and non-financial information in the Directors' Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

Opinion on financial statements

In our opinion:

- the financial statements give a true and fair view of the state of the group's and the parent company's affairs as at 30 June 2016 and of the group's profit for the year then ended;
- the group's financial statements have been properly prepared in accordance with IFRSs as adopted by the European Union;
- the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

Emphasis of matters

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in Note 14 to the financial statements considering the group's intangible asset holdings as at 30 June 2016, and the disclosure made in Note 1.2 to the financial statements considering the group's ability to continue as a going concern.

We draw attention to Note 14 in the financial statements, which indicates that there is uncertainty as to the quantum of future economic benefits which may be generated by the Colour Match app, valued at \$16,329,879 at 30 June 2016.

MICROSKIN PLC

INDEPENDENT AUDITORS' REPORT TO THE SHAREHOLDERS FOR THE YEAR ENDED 30 JUNE 2016

We also draw attention to Note 1.2 in the financial statements, which indicates that the group paid operating expenses of \$544,858 during the year, but only has cash at 30 June 2016 of \$16,933.

We believe that the group's ability to continue as a going concern is dependent on the group securing additional funding through shareholder loans, or successful realisation of revenue growth via the Group's plans to expand their franchise locations and sales in the coming year.

As a result, there is a material uncertainty related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern, and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report. The financial statements do not include the adjustments that would result if the company were unable to continue as a going concern.

Remuneration Report

We have audited the director's remuneration report, shown on page 9 of the directors' report, for the year ended 30 June 2016. The directors of the Group are responsible for the preparation and presentation of the Remuneration Report in accordance with section 421 of the *Companies Act 2006*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit, in accordance with section 497 of the *Companies Act 2006*.

Opinion on Remuneration Report

In our opinion, the part of the Director's Remuneration Report to be audited has been properly prepared in accordance with the *Companies Act 2006*.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion the information given in the Strategic Report and the Directors' Report for the financial period for which the financial statements are prepared is consistent with the financial statements.


Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

MICROSKIN PLC

INDEPENDENT AUDITORS' REPORT TO THE SHAREHOLDERS FOR THE YEAR ENDED 30 JUNE 2016



Nicholas Hollens – Senior Statutory Auditor
For and on behalf of KSI (WA) – Statutory Auditors

35 Outram Street
West Perth WA 6005
Australia

2 December 2016

MICROSKIN PLC

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2016

		Year ended 30 June 2016	Year ended 30 June 2015
	Note	\$	\$
Revenue	2	378,006	548,417
Cost of sales		(64,946)	(30,776)
Gross Profit		313,060	517,641
Other operating income	2	3,393	254,271
Administrative expense		(609,945)	(611,498)
Marketing expenses		(24,347)	(24,005)
Occupancy expenses		(62,937)	(59,002)
Finance costs		(64,004)	(70,568)
Bad debt expense		(4,846)	-
(Loss)/Profit before income tax	3	(449,626)	29,695
Income tax (expense)/benefit	5	-	(26,036)
(Loss)/Profit for the year		(449,626)	3,659
Other comprehensive income:			
Exchange differences on translating foreign controlled entities		(120,013)	(10,655)
Total comprehensive income for the year		(569,639)	(6,996)
Basic & diluted earnings/(loss) per share (in cents)	8	(0.00)	(0.00)

All of the activities of the Group are classed as continuing.

All of the total comprehensive income for the period is attributable to the owners of the Group.

MICROSKIN PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2016


		30 June 2016	30 June 2015
			As restated
Note	\$	\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	9	16,933	6,388
Trade and other receivables	10	422,632	371,185
Inventories	11	86,422	42,491
Other assets	12.1	3,062,432	15,593
TOTAL CURRENT ASSETS		3,588,419	435,657
NON-CURRENT ASSETS			
Property, plant and equipment	13	51,659	56,479
Intangible assets	14.1	16,589,966	16,589,138
TOTAL NON-CURRENT ASSETS		16,641,625	16,645,617
TOTAL ASSETS		20,230,044	17,081,274
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	15	642,472	408,772
Borrowings	16	895,180	605,307
Shares to be issued	17	-	16,329,879
TOTAL CURRENT LIABILITIES		1,537,652	17,343,958
NON-CURRENT LIABILITIES			
Borrowings	16	20,320	-
TOTAL NON-CURRENT LIABILITIES		20,320	-
TOTAL LIABILITIES		1,557,972	17,343,958
NET ASSETS		18,672,072	(262,684)
EQUITY			
Issued capital	18	25,878,757	13,425,955
Share premium		7,284,694	233,101
Reserves	19	(11,486,186)	(11,366,173)
Accumulated losses		(3,005,193)	(2,555,567)
TOTAL EQUITY		18,672,072	(262,684)

MICROSKIN PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2016

These financial statements were approved and authorised for release by the Directors on 2 December 2016 and are signed on its behalf by:

A handwritten signature in black ink, appearing to read 'B Amor', is centered on the page. The signature is fluid and cursive, with a long horizontal stroke extending to the right.

B Amor
Director

Company registration number: 0832699

MICROSKIN PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 JUNE 2016

	Ordinary Share Capital	Share Premium	Merger Reserve	Accumulated Losses	Foreign Currency Reserve	Total Equity
	\$		\$	\$	\$	\$
Opening balance 1 July 2014	13,122,223	-	(11,397,975)	(2,559,226)	42,457	(792,521)
Comprehensive Income						
Profit for the year	-	-	-	3,659	-	3,659
Other comprehensive income	-	-	-	-	(10,655)	(10,655)
Total comprehensive income for the ear	-	-	-	3,659	(10,655)	(6,996)
Transactions with owners, in their capacity as owners						
Shares issued in settlement of creditors [as restated]	303,732	233,101	-	-	-	536,833
Balance as at 30 June 2015 [as restated]	13,425,955	233,101	(11,397,975)	(2,555,567)	31,802	(262,684)
Opening balance 1 July 2015	13,425,955	233,101	(11,397,975)	(2,555,567)	31,802	(262,684)
Comprehensive Income						
Profit for the year	-	-	-	(449,626)	-	(449,626)
Other comprehensive income	-	-	-	-	(120,013)	(120,013)
Total comprehensive income for the ear	-	-	-	(449,626)	(120,013)	(569,639)
Transactions with owners, in their capacity as owners						
Shares issued to acquire subsidiary	9,402,124	7,051,593	-	-	-	16,453,717
Shares issued in respect of share subscription facility	3,050,678	-	-	-	-	3,050,678
Balance as at 30 June 2016	25,878,757	7,284,694	(11,397,975)	(3,005,193)	(88,211)	18,672,072

MICROSKIN PLC

CONSOLIDATED STATEMENT OF CASHFLOWS

FOR THE YEAR ENDED 30 JUNE 2016

		Year ended 30 June 2016	Year ended 30 June 2015
Note	\$		
CASH FLOWS FROM OPERATING ACTIVITIES:			
		339,334	345,871
		(544,858)	(727,652)
		(64,004)	(70,568)
		-	(23,450)
		<u> </u>	<u> </u>
20		(269,528)	(475,799)
CASH FLOWS FROM INVESTING ACTIVITIES:			
		(17,692)	(11,747)
		(12,428)	(9,525)
		<u> </u>	<u> </u>
		(30,120)	(21,272)
CASH FLOWS FROM FINANCING ACTIVITIES:			
		-	(65,184)
		310,193	573,721
		<u> </u>	<u> </u>
		310,193	508,537
		10,545	11,466
9		<u>6,388</u>	<u>(5,078)</u>
9		<u>16,933</u>	<u>6,388</u>

MICROSKIN PLC

PARENT COMPANY STATEMENT OF FINANCIAL POSITION

FOR THE YEAR ENDED 30 JUNE 2016

		30 June 2016	30 June 2015
			(as restated)
	Note	\$	\$
ASSETS			
CURRENT ASSETS			
Intercompany Loan		317,575	459,516
Other Loans Receivable		99,873	-
Other assets	12.2	3,050,678	-
TOTAL CURRENT ASSETS		3,468,126	459,516
NON-CURRENT ASSETS			
Intangible Assets	14.2	16,329,879	16,329,879
TOTAL NON-CURRENT ASSETS		16,329,879	16,329,879
TOTAL ASSETS		19,798,005	16,789,395
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables		20,500	20,500
Shares to be issued	17	-	16,329,879
TOTAL CURRENT LIABILITIES		20,500	16,350,379
NON-CURRENT LIABILITIES			
TOTAL NON-CURRENT LIABILITIES		-	-
TOTAL LIABILITIES		20,500	16,350,379
NET ASSETS		19,777,505	439,015
EQUITY			
Issued capital	18	25,878,757	13,425,955
Share premium	18	7,284,694	233,101
Reserves		(191,420)	(34,188)
Accumulated losses		(13,194,526)	(13,185,853)
TOTAL EQUITY		19,777,505	439,015

In accordance with section 408 of the UK Companies Act 2006, the company is availing itself of the exemption from presenting its individual statement of profit or loss and other comprehensive income. The company's loss for the financial year as determined in accordance with IFRS's is \$8,673 (2015: loss of \$53,514). The company had no cashflow in the period, and therefore no cashflow statement has been prepared.

MICROSKIN PLC

PARENT COMPANY STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 JUNE 2016

	Ordinary Share Capital \$	Share Premium \$	Foreign Exchange Reserve \$	Accumulated Losses \$	Total Equity \$
Opening balance 1 July 2014	13,122,223	-	-	(13,132,339)	(10,116)
Comprehensive income					
Profit for the period	-	-	-	(53,514)	(53,514)
Other comprehensive income	-	-	(34,188)	-	(34,188)
Total comprehensive income for the period	-	-	(34,188)	(53,514)	(87,702)
Transactions with owners, in their capacity as owners					
Shares issued in settlement of creditors [as restated]	303,733	233,101	-	-	536,834
Total transactions with owners, in their capacity as owners [as restated]	303,733	233,101	-	-	536,834
Balance as at 30 June 2015	13,425,956	233,101	(34,188)	(13,185,853)	439,015
Opening balance 1 July 2015	13,425,956	233,101	(34,188)	(13,185,853)	439,015
Comprehensive income					
Loss for the period	-	-	-	(8,673)	(8,673)
Other comprehensive income	-	-	(157,232)	-	(157,232)
Total comprehensive income for the period	-	-	(157,232)	(8,673)	(165,905)
Transactions with owners, in their capacity as owners					
Shares issued to acquire subsidiary	9,402,124	7,051,593	-	-	16,453,717
Shares issued in respect of share subscription facility	3,050,678	-	-	-	3,050,678
Total transactions with owners, in their capacity as owners	12,452,802	7,051,593	-	-	19,504,395
Balance as at 30 June 2016	25,878,758	7,284,694	(191,420)	(13,194,526)	19,777,505

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

The consolidated financial statements and notes represent those of Microskin PLC and its controlled entities ("the consolidated group" or "group"). The consolidated financial statements have been prepared for the year ending 30 June 2016.

1. Significant accounting policies

1.1 Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS. The financial statements are drawn up under the historical cost convention.

IFRS, issued by the International Accounting Standards Board (IASB), set out accounting policies that the IASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of the financial statements are presented below and have been consistently applied unless otherwise stated.

1.2 Going Concern

This report has been prepared on the going concern basis, which contemplates the continuation of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

As at 30 June 2016 the Group had a cash balance of \$16,933, while during the year it made payments to suppliers and employees totalling \$544,858.

The Group has now embarked on an aggressive rollout of clinics throughout the world with franchises opening in Turkey, India, United Kingdom, France, Brazil and throughout Asia.

Further expansion of the licensed clinic network in the coming year will see clinic revenues cover fixed overheads and then start to contribute modest profits in future years. Negotiations continue with various multinationals which can potentially result in significant revenue streams to the Group.

In the short term, monies are being advanced to the company by the director, Mr Amor, to assist with day to day cashflow needs, until the Group's revenue streams grow to enable the company to be self sufficient. In light of these events and expected future developments, the Directors are confident that the Group has access to sufficient funds, now and in the future, to meet its working capital requirements for the coming year.

However, the Directors also recognise that the ability of the Group to continue as a going concern and to pay its debts as and when they fall due is dependent on Mr Amor's support and on the Group's future sales and success in generating further franchise arrangements. Given the current cash position, there is a material uncertainty about whether the Group can continue as a going concern.

Should the Group be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the normal course of business and at amounts different from those stated in the financial report. The financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts nor to the amounts and classification of liabilities that may be necessary should the Group be unable to continue as a going concern.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

1.3 Principles of Consolidation

The consolidated financial statements incorporate the assets, liabilities and results of entities controlled by Microskin PLC at the end of the reporting period. A controlled entity is any entity over which Microskin PLC has the power to govern the financial and operating policies so as to obtain benefits from its activities.

In preparing the consolidated financial statements, all intragroup balances and transactions between entities in the consolidated group have been eliminated in full on consolidation.

In the company statement of financial position investment in subsidiaries is accounted for at the nominal value of the shares issued on acquisition.

Asset Acquisitions

When the Group acquires a new company, but that company does not constitute a “business” under IFRS 3 (i.e. it is an asset holding company), the consideration transferred in relation to the acquisition is attributed to the assets of the acquiree.

1.4 Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of manufactured products includes direct materials, direct labour and an appropriate portion of variable and fixed overheads. Overheads are applied on the basis of normal operating capacity. Costs are assigned on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts.

1.5 Property, Plant and Equipment

Plant and equipment

Plant and equipment are measured on the cost basis less depreciation and impairment losses. Cost includes expenditure that is directly attributable to the asset.

Depreciation

The depreciable amount of all fixed assets including capitalised leased assets is depreciated on a reducing balance basis over the asset’s useful life to the Group commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements. Land is not depreciated.

The depreciation rates used for each class of depreciable assets are:

Class of Fixed Asset	Depreciation Rate
Plant and Equipment	5 – 66%
Motor Vehicles	25%
Leasehold improvements	2.5 – 10%

The assets’ residual values, depreciation methods and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of comprehensive income.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

1.6 Financial instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is the equivalent to the date that the Group commits itself to either the purchase or sale of the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transactions costs, except where the instrument is classified 'at fair value through profit or loss' in which case transaction costs are expensed to profit or loss immediately.

Classification and subsequent measurement

Financial instruments are subsequently measured at either fair value, amortised cost using the effective interest rate method, or cost. *Fair value* represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties in arm's length transaction. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

Amortised cost is calculated as:

- a) The amount at which the financial asset or financial liability is measured at initial recognition;
- b) Less principal repayments;
- c) Plus or minus the cumulative amortisation of the difference, if any, between the amount initially recognised and the maturity amount calculated using the *effective interest method*; and
- d) Less any reduction for impairment.

The *effective interest method* is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying value with a consequential recognition of an income or expense in profit or loss.

The classification of financial instruments depends on the purpose for which the investments were acquired. Management determines the classification of its investments at initial recognition and at the end of each reporting period for held-to-maturity assets.

The group does not designate any interest as being subject to the requirements of accounting standards specifically applicable to financial instruments.

(i) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost.

Loans and receivables are included in current assets, except for those which are not expected to mature within 12 months after the end of the reporting period.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

(ii) Financial liabilities

Non-derivative financial liabilities (excluding financial guarantees) are subsequently measured at amortised cost. Fees payable on the establishment of loan facilities are recognised as transaction costs of the loan.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.

Fair value

Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value for all unlisted securities, including recent arm's length transactions, reference to similar instruments and option pricing models.

Impairment

Objective evidence that a financial asset is impaired includes default by a debtor, evidence that the debtor is likely to enter bankruptcy or adverse economic conditions in the stock exchange. At the end of each reporting period, the group assesses whether there is objective evidence that a financial asset has been impaired through the occurrence of a loss event. In the case of available-for-sale financial instruments, a significant or prolonged decline in the value of the instrument is considered to indicate that an impairment has arisen.

Where a subsequent event causes the amount of the impairment loss to decrease (e.g. payment received), the reduction in the allowance account (provision for impairment of receivables) is taken through profit and loss.

Impairment losses are recognised through an allowance account for loans and receivables in the statement of comprehensive income.

Derecognition

Financial assets are derecognised where the contractual rights to receipt of cash flows expires or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised where the related obligations are either discharged, cancelled or expired. The difference between the carrying value of the financial liability extinguished or transferred to another party and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

When available-for-sale investments are sold, the accumulated fair value adjustments recognised in other comprehensive income are reclassified to profit or loss.

1.7 Impairment of non-financial assets

At the end of each reporting period, the group assesses whether there is any indication that an asset may be impaired. The assessment will include the consideration of external and internal sources of information and dividends received from subsidiaries, associates or jointly controlled entities deemed to be out of pre-acquisition profits. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use to the asset's carrying value. Value in use is calculated by discounting the estimated future cash flows of the asset or cash-generating unit (CGU) at a pre-tax discount rate reflecting the specific risks in the asset / CGU. Any excess of the asset's carrying value over its recoverable amount is expensed to the statement of comprehensive income.

Where it is not possible to estimate the recoverable amount of an individual asset, the group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

Impairment losses recognised in respect of CGU's are allocated first to reduce the carrying amount of goodwill to nil and then to the other assets in the unit in proportion to their carrying amount.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

Assets, other than goodwill that have an allocated impairment loss are reviewed for reversal indicators at the end of each reporting period. After recognition of an impairment loss, the amortisation charge for the asset is adjusted in future periods to allocate the asset's revised carrying amount on a systematic basis over its remaining useful life.

Impairment losses are recognised as an expense immediately, unless the relevant asset is property, plant and equipment held at fair value (other than investment property carried at a revalued amount) in which case the impairment loss is treated as a revaluation decrease as described in the accounting policy for property, plant and equipment.

1.8 Intangibles

Patents and trademarks are recognised at cost of acquisition. Patents and trademarks have a finite life and are carried at cost less any accumulated amortisation and any impairment losses. Patents and trademarks are amortised over their useful life, which is estimated at 20 years, hence amortisation is charged at 5% per annum.

Computer software

Computer apps and software assets are recognised at cost of acquisition. Apps and software have a finite life and are carried at cost less any accumulated amortisation and any impairment losses. Computer apps and software assets are amortised over their useful life, commencing from the date they are ready for use.

At 30 June 2016, the only software asset held is not yet ready for use, hence no useful life has been estimated, and no amortisation policy has been set.

1.9 Research and Development

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project is expected to deliver future economic benefits and these benefits can be measured reliably.

Development costs have a finite life and are amortised on a systematic basis based on the future economic benefits over the useful life of the project.

1.10 Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less which are convertible to a known amount of cash and subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

1.11 Provisions

Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

Provisions are measured using the best estimate of the amounts required to settle the obligation at the end of the reporting period.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

1.12 Trade and other payables

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Group during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

1.13 Revenue

Interest

Interest income is recognised using the effective interest method.

Franchise Fees

Franchise fees are amounts specified by contracts between the group and its franchisees. The contracts specify dates when fee amounts are to be invoiced. There are no other conditions affecting recognition of this revenue, thus it is governed by the contract dates.

Sales

Revenue from the sale of goods is recognised at the point of delivery as this corresponds to the transfer of significant risks and rewards of ownership of the goods and the cessation of all involvement in those goods.

Royalties & Government subsidies

Royalties & Government subsidies are accounted for on an accruals basis, with receipts apportioned over the period that the amount received relates to.

1.14 Impairment of assets

At the end of each reporting period, the Group assesses whether there is any indication that an asset may be impaired. The assessment will include the consideration of external and internal sources of information. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount in accordance with another Standard. Any impairment loss of a revalued asset is treated as a revaluation decrease in accordance with that other Standard.

Inventory is regularly assessed for potential indicators of impairment.

1.15 Share capital

Ordinary shares are classified as equity. Mandatorily redeemable preference shares are classified as liabilities. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds. Where any group company purchases the company's equity share capital (treasury shares), the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the company's equity holders until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the company's equity holders.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

1.16 Income Tax

The income tax expense (revenue) for the period comprises current income tax expense (income) and deferred tax expense (income).

Current income tax expense charged to the profit or loss is the tax payable on taxable income calculated using applicable income tax rates enacted, or substantially enacted, as at the end of the reporting period. Current tax liabilities (assets) are therefore measured at the amounts expected to be paid to (recovered from) the relevant taxation authority.

Deferred income tax expense reflects movements in deferred tax asset and deferred tax liability balances during the period as well as unused tax losses.

Current and deferred income tax expense (income) is charged or credited outside profit or loss when the tax relates to items that are recognised outside profit or loss.

Deferred tax assets and liabilities are ascertained based on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets also result where amounts have been fully expensed but future tax deductions are available. No deferred income tax will be recognised from the initial recognition of an asset or liability, excluding a business combination, where there is no effect on accounting or taxable profit or loss.

Deferred tax assets and liabilities are calculated at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates enacted or substantively enacted at the end of the reporting period. Their measurement also reflects the manner in which management expects to recover or settle the carrying amount of the related asset or liability.

Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is probable that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.

Current assets and liabilities are offset where a legally enforceable right of set-off exists and it is intended that net settlement or simultaneous realisation and settlement of the respective asset and liability will occur. Deferred tax assets and liabilities are offset where a legally enforceable right of set-off exists, the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where it is intended that net settlement or simultaneous realisation and settlement of the respective asset and liability will occur in future periods in which significant amounts of deferred tax assets or liabilities are expected to be recovered or settled.

1.17 Leases

Leases of fixed assets where substantially all the risks and benefits incidental to the ownership of the asset, but not the legal ownership that are transferred to the Group are classified as finance leases.

Finance leases are capitalised by recording an asset and a liability at the lower of the amounts equal to the fair value of the leased property or the present value of the minimum lease payments, including any guaranteed residual values. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for that period.

Leased assets are depreciated on a straight-line basis over their estimated useful lives where it is likely that the Group will obtain ownership of the asset or over the term of the lease.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

Lease payments for operating leases, where substantially all of the risks and benefits remain with the lessor, are charged as expenses on a straight-line basis over the life of the lease term.

Lease incentives under operating leases are recognised as a liability and amortised on a straight-line basis over the life of the lease term.

1.18 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to prepare for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

1.19 Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

1.20 Foreign currency transactions and balances

Functional and presentation currency

The functional currency of each of Microskin PLC's entities is measured using the currency of the primary economic environment in which that entity operates. The financial statements are presented in Australian dollars which is the parent entity's functional and presentation currency.

Transaction and balances

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items are recognised in the statement of comprehensive income, except where deferred in equity as a qualifying cash flow or net investment hedge.

Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in the statement of comprehensive income.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

Group companies

The financial results and position of foreign operations whose functional currency is different from Microskin PLC's presentation currency are translated as follows:

- assets and liabilities are translated at period-end exchange rates prevailing at that reporting date;
- income and expenses are translated at average exchange rates for the period where the average rate approximates the rate at the date of the transaction; and
- retained earnings are translated at the exchange rates prevailing at the date of the transaction.

Exchange differences arising on translation of foreign operations are transferred directly to Microskin PLC's foreign currency translation reserve in the statement of financial position. These differences are recognised in the statement of comprehensive income in the period in which the operation is disposed.

1.21 Leases

The Group leases certain fixed assets, classified as motor vehicles. Leases of motor vehicles where the Group has substantially all the risks and rewards of ownership are classified as finance leases (or hire purchase). Finance leases are capitalised at the lease's commencement date, at the lower of the fair value of the leased asset, and the present value of the minimum lease payments.

Each lease payment is allocated between the liability and finance charges. The corresponding rental obligations, net of finance charges, are included in short term (payments in less than 12 months) and long term (payments in more than 12 months) borrowings. The interest element of the finance cost is charged to the income statement over the lease period, so as to produce a constant periodic rate of interest on the remaining balance of the liability each period. The motor vehicles acquired are depreciated over the shorter of the useful life of the asset and the lease term.

1.22 Key estimates and judgements

The directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Group.

Estimation of useful lives of assets

The Group determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Impairment of non-financial assets other than goodwill and other indefinite life intangible assets

The Group assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. If any impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs to sell, or value-in-use calculations, which incorporate a number of key estimates and assumptions.

1.23 Prior year adjustment

During this financial year the company identified that, due to an administrative oversight, certain amounts received in respect of shares issued had not been split between share capital (value up to par), and share premium (all value in excess of par). Instead all amounts had been attributed to share capital.

A full reconciliation exercise has been completed, which has the following impact on the comparative figures:

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

Restatement of Statement of Financial Position:

	30 June 2015	Adjustment	30 June 2015
	Original		Restated
	\$	\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	6,388	-	6,388
Trade and other receivables	371,185	-	371,185
Inventories	42,491	-	42,491
Other assets	15,593	-	15,593
TOTAL CURRENT ASSETS	435,657	-	435,657
NON-CURRENT ASSETS			
Property, plant and equipment	56,479	-	56,479
Intangible assets	16,589,138	-	16,589,138
TOTAL NON-CURRENT ASSETS	16,645,617	-	16,645,617
TOTAL ASSETS	17,081,274	-	17,081,274
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	353,065	-	353,065
Borrowings	605,307	-	605,307
Provisions	55,707	-	55,707
Shares to be issued	16,329,879	-	16,329,879
TOTAL CURRENT LIABILITIES	17,343,958	-	17,343,958
NON-CURRENT LIABILITIES			
Borrowings	-	-	-
TOTAL NON-CURRENT LIABILITIES	-	-	-
TOTAL LIABILITIES	17,343,958	-	17,343,958
NET ASSETS	(262,684)	-	(262,684)
EQUITY			
Issued capital	13,659,056	(233,101)	13,425,955
Share premium	-	233,101	233,101
Reserves	(11,366,173)	-	(11,366,173)
Accumulated losses	(2,555,567)	-	(2,555,567)
TOTAL EQUITY	(262,684)	-	(262,684)

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

Restatement of Statement of Changes in Equity:

	Ordinary Share Capital	Share Premium	Merger Reserve	Foreign Exchange Reserve	Accumulated Losses	Total Equity
	\$	\$	\$	\$	\$	\$
Opening balance 1 July 2014	13,122,223	-	(11,397,975)	42,457	(2,559,226)	(792,521)
Comprehensive income						
Profit for the period	-	-	-	-	3,659	3,659
Other comprehensive income	-	-	-	(10,655)	-	(10,655)
Total comprehensive income for the period	-	-	-	(10,655)	3,659	(6,996)
Transactions with owners, in their capacity as owners						
Shares issued in settlement of creditors [as previously reported]	536,833	-	-	-	-	536,833
<i>Effect of changes in accounting policy</i>	<i>(233,101)</i>	<i>233,101</i>				
Total transactions with owners, in their capacity as owners [as restated]	303,732	233,101				536,833
Balance as at 30 June 2015 [as restated]	13,425,955	233,101	(11,397,975)	31,802	(2,555,567)	(262,684)

It is noted that the above change has no cashflow or profit and loss impact, therefore neither of those statements have been reproduced here.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

1.24 New accounting standards for application in future periods

- (a) New and amended standards adopted by the group

There are no IFRSs or IFRIC interpretations that are effective for the first time for the financial period beginning on 1 July 2015 that would be expected to have a material impact on the group.

- (b) New standards and interpretations not yet adopted

A number of new standards and amendments to standards and interpretations are effective for annual periods beginning on or after 1 July 2016, and have not been applied in preparing these consolidated financial statements. None of these is expected to have a significant effect on the financial statements of the group, except the following set out below:

IFRS 9, 'Financial instruments', addresses the classification, measurement and recognition of financial assets and financial liabilities. IFRS 9 was issued in November 2009 and October 2010. It replaces the parts of IAS 39 that relate to the classification and measurement of financial instruments. IFRS 9 requires financial assets to be classified into two measurement categories:

- 1) those measured as at fair value and 2) those measured at amortised cost. The determination is made at initial recognition.

The classification depends on the entity's business model for managing its financial instruments and the contractual cash flow characteristics of the instrument. For financial liabilities, the standard retains most of the IAS 39 requirements. The main change is that, in cases where the fair value option is taken for financial liabilities, the part of a fair value change due to an entity's own credit risk is recorded in other comprehensive income rather than the income statement, unless this creates an accounting mismatch. The group is yet to assess IFRS 9's full impact and intends to adopt IFRS 9 no later than the accounting period beginning on 1 July 2016. The group will also consider the impact of the remaining phases of IFRS 9 when completed by the Board.

2. Revenue and Other Income

	Year ended 30 June 2016	Year ended 30 June 2015
Note	\$	\$
Sales revenue		
- Sale of goods	184,211	193,543
- Franchise fees	125,299	295,000
- Royalties	68,496	59,874
	378,006	548,417
Other revenue		
- Interest revenue	-	350
- Other revenue	3,393	10,958
- Debt forgiveness	-	243,031
- Currency (Loss)/Gain	-	(68)
	3,393	254,271
Total Revenue	381,399	802,688

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

3. Operating loss

The following items have been included in arriving at the operating loss:

	Year ended June 2016 \$	Year ended June 2015 \$
Depreciation on property, plant and equipment	16,954	17,164
Amortisation on intangible assets	17,158	16,469
Bad debt expense	4,846	-
Directors' remuneration	-	-
Auditor's remuneration		
- As auditors (for Microskin PLC)	8,500	7,500
- As tax agents (for Microskin PLC – tax compliance)	2,500	2,000
- As auditors (for Microskin Holdings Limited)	8,500	7,500

All remuneration payable to the auditors has been disclosed above. No other non-audit services have been provided. No benefits in kind are payable to the auditors.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

4. Segment Information

The board of directors is the group's chief operating decision-maker. The board has determined the operating segments based on the information reviewed by the board for the purposes of allocating resources and assessing performance.

The board considers the business from both a geographic and product perspective. Geographically, management considers the performance in Australia, the USA, Scandinavia & the Baltics, South East Asia, India, Turkey & Saudi Arabia. These are locations that house either a Microskin group owned and operated clinic, or a franchised clinic. From a product perspective, at this stage in the group's life cycle, management consider there to be only one product: Microskin.

Location	Revenue	Revenue
	Year ended 30 June 2016	Year ended 30 June 2015
	\$	\$
Australia	197,992	459,242
United States of America	50,638	45,087
Scandinavia & the Baltics	7,897	8,008
Turkey	9,962	6,779
Saudi Arabia	-	120,000
Brazil	-	175,000
Canada	125,299	
	<hr/> 391,788	<hr/> 814,116

All locations outside of Australia are operated under franchise agreements. For this reason, all operating costs are attributed by management to the Australian segment. Income from outside of Australia is derived without the occurrence of overhead costs.

All group assets are attributed to the Australian segment. As noted above, the revenues from other geographic locations are from franchise arrangements. The Group does not have assets in those countries.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

5. Income Tax Expense

		Year ended 30 June 2016	Year ended 30 June 2015
	Note	\$	\$
Current tax expense			
R&D Tax Offset Receivable		-	-
R&D Tax Offset (previous overpayment)		-	26,036
Deferred tax expense			
Derecognition of deferred tax asset that is no longer probable to be utilised		-	-
Income tax (benefit) from continuing operations		-	26,036
		-	26,036

Factors affecting the current tax charge year ended 2016

	UK Activities (tax at 20%)	Australian Activities (tax at 30%)	Total
	\$	\$	\$
(Loss)/Profit before tax	(8,673)	(440,953)	(449,626)
Prima facie tax payable on profit from ordinary activities before income tax	(1,735)	(132,286)	(134,021)
Reconciliation to income/charge:			
- other non-allowable items	-	5,684	5,684
- foreign income	-	2,022	2,022
- brought forward losses applied against profits	-	-	-
- current period loss carried forward	1,735	124,580	126,315
Income tax (benefit)	-	-	-

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

Factors affecting the tax charge year ended 2015

	UK Activities (tax at 22.5%)	Australian Activities (tax at 30%)	Total
	\$	\$	\$
Loss before tax	(53,514)	83,209	29,965
Prima facie tax payable on profit from ordinary activities before income tax	(10,703)	24,963	14,260
Reconciliation to income/charge:			
- other non-allowable items	-	9,981	9,981
- foreign income	-	637	637
- R&D expenditure	-	26,036	26,036
- R&D concessions	-	(35,581)	(35,581)
- current period loss carried forward	10,703	-	10,703
Income tax (benefit)	-	26,036	26,036

6. Interests of Key Management Personnel

The totals of remuneration payable to the key management personnel of Microskin PLC during the period are as follows:

	Year ended 30 June 2016	Year ended 30 June 2015
	\$	\$
Barry Lowndes	137,400	-
Barry Amor ¹	-	-
Scott McTaggart	-	-
David Merson	-	-
	137,400	-

¹ During the prior year, Mr Amor's company, Zeehe Pty Ltd, provided Microskin with a credit note for his previous charges as managing director (see Note 24)

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

Key management personnel shareholdings

The number of ordinary shares in Microskin PLC held by each key management person of Microskin PLC during the financial year is as follows:

30 June 2016	Balance at beginning of year	Acquired during the year	Disposed during the year	Balance at end of year
Barry Lowndes	3,721,802	-	-	3,721,802
Barry Amor	5,764,522	-	-	5,764,522
Scott McTaggart	165,625	-	-	165,625
David Merson	208,333	-	-	208,333
	9,860,282	-	-	9,860,282

30 June 2015	Balance at beginning of year	Acquired during the year	Disposed during the year	Balance at end of year
Barry Lowndes	3,721,802	-	-	3,721,802
Barry Amor	1,901,732	3,975,780	(112,990)	5,764,522
Scott McTaggart	165,625	-	-	165,625
David Merson	208,333	-	-	208,333
	5,997,492	3,975,780	(112,990)	9,860,282

Other key management personnel transactions

For details of other transactions with key management personnel, refer to Note 24: Related Party Transactions.

7. Employees

	Year ended 30 June 2016	Year ended 30 June 2015
	\$	\$
Staff costs for the Group during the period:		
Wages and salaries	307,295	181,603
Superannuation (pension)	15,557	23,410
Social security costs	-	-
	322,852	205,013

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

The average monthly number of staff (including executive Directors) employed by the Group during the period amounted to:

	Year ended 30 June 2016	Year ended 30 June 2015
Management staff	6	6
Executive Directors	1	1
Total	7	7

8. Earnings per share

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the company by the weighted average number of ordinary shares in issue during the period.

The following reflects earnings and share data used in the earnings per share calculation.

	Year ended 30 June 2016 \$	Year ended 30 June 2015 \$
Profit/(loss) for the period	(449,626)	3,659
Weighted average number of shares	141,707,131	89,438,220

Please note, on 17 March 2016, a 10:1 share split was completed by the Company, increasing the share capital in existence at that date by a factor of ten. In order to preserve comparability of the earnings per share figures, the prior year weighted average number of shares, and this year's for the first eight months, have been adjusted as though the share split had always been in place.

There were no instruments (e.g. redeemable preference shares or share options) in issue as at 30 June 2016 that could potentially dilute earnings per share in the future.

9. Cash and cash equivalents – group

	30 June 2016 \$	30 June 2015 \$
Cash at bank and in hand	16,933	6,388
	16,933	6,388

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

10. Trade and other receivables – group

	30 June 2016	30 June 2015
Note	\$	\$
CURRENT		
Trade receivables	487,632	436,185
Provision for doubtful debts	(65,000)	(65,000)
	<u>422,632</u>	<u>371,185</u>
Other receivables – R&D Offset	5 -	-
Total current trade and other receivables	<u>422,632</u>	<u>371,185</u>

11. Inventories – group

	30 June 2016	30 June 2015
	\$	\$
CURRENT		
Finished goods	86,422	42,491
	<u>86,422</u>	<u>42,491</u>

During the year, the amount of inventory recognised as an expense was \$31,267.

12. Other assets

12.1 Group

	30 June 2016	30 June 2015
	\$	\$
CURRENT		
Prepayments	9,253	13,093
Bonds	2,500	2,500
Unpaid shares	3,050,679	-
	<u>3,062,432</u>	<u>15,593</u>

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

12.2 Parent Company

	30 June 2016 \$	30 June 2015 \$
CURRENT		
Unpaid shares	3,050,679	-
	3,050,679	-

13. Property, plant and equipment – group

	Motor Vehicles \$	Plant & Equipment \$	Leasehold Improvements \$	Total \$
Cost				
At 1 July 2015	54,438	107,361	21,323	183,122
Additions	-	12,428	-	12,428
Disposals	-	(43,153)	(1,150)	(44,303)
As at 30 June 2016	54,438	76,636	20,173	151,247
Accumulated Depreciation				
At 1 July 2015	(33,266)	(85,724)	(7,653)	(126,643)
Charged	(5,308)	(10,731)	(916)	(16,955)
Disposals	-	42,918	1,092	44,010
As at 30 June 2016	(38,574)	(53,537)	(7,477)	(99,588)
Net book value				
Cost	54,438	76,636	20,173	151,247
Accumulated Depreciation	(38,574)	(53,537)	(7,477)	(99,588)
As at 30 June 2016	15,864	23,099	12,696	51,659
Cost	54,438	107,361	21,323	183,122
Accumulated Depreciation	(33,266)	(85,724)	(7,653)	(126,643)
As at 30 June 2015	21,172	21,637	13,670	56,479

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

14. Intangible Assets

14.1 Group

	Patent, trademarks and other rights \$	Computer Software \$	Total \$
Cost			
At 1 July 2015	343,244	16,379,614	16,722,858
Additions	17,985	-	17,985
As at 30 June 2016	361,229	16,379,614	16,740,843
Accumulated amortisation			
At 1 July 2015	(83,985)	(49,735)	(133,720)
Amortisation charge	(17,157)	-	(17,157)
As at 30 June 2016	(101,142)	(49,735)	(150,877)
Net book value			
Cost	361,229	16,379,614	16,740,843
Accumulated Depreciation	(101,142)	(49,735)	(150,877)
As at 30 June 2016	260,087	16,329,879	16,589,966
Cost	343,244	16,379,614	16,722,858
Accumulated Depreciation	(83,985)	(49,735)	(133,720)
As at 30 June 2015	259,259	16,329,879	16,589,138

On 23 June 2015, the Board completed the acquisition of Mobilespectra Pty Ltd for \$16,329,879. This transaction was accounted for as an asset acquisition. The consideration for the transaction was attributed to the single asset acquired: a colour matching app for the second skin products produced under the Microskin brand. It is anticipated that this app will form the cornerstone of a major expansion in online sales for the company.

The company has continued to develop the acquired app diligently during this financial year, but it was not ready for use at the year end. As such, the Board is not in a position to evaluate the expected useful life of the app and hence, amortisation of the asset has not commenced.

The value of an intangible is representative of expected future cashflows that will be generated from the asset's future use by the business. At this stage, the Board are not in a position to calculate projections of the asset's impact on the future sales. While the Directors are optimistic for the impact of the Colour Match app on sales and future revenues, at this stage there is a degree of uncertainty as to whether the full value of the intangible asset shown above will be recovered in future sales.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

14.2 Parent Company

	Computer Software	Total
	\$	\$
Cost		
At 1 July 2015	16,329,879	16,329,879
Additions	-	-
As at 30 June 2016	16,329,879	16,329,879
Accumulated amortisation		
At 1 July 2015	-	-
Amortisation charge	-	-
As at 30 June 2016	-	-
Net book value		
Cost	16,329,879	16,329,879
Accumulated Depreciation	-	-
As at 30 June 2016	16,329,879	16,329,879
Cost	16,329,879	16,329,879
Accumulated Depreciation	-	-
As at 30 June 2015	16,329,879	16,329,879

15. Trade and other payables – group

	30 June 2016	30 June 2015
Note	\$	\$
CURRENT		
<i>Unsecured liabilities</i>		
Trade payables	271,187	118,391
Sundry payables and accrued expenses	314,488	234,674
Employee leave provisions	56,797	55,707
	642,472	408,772

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

16. Borrowings – group

	30 June 2016	30 June 2015
Note	\$	\$
CURRENT		
<i>Secured liabilities:</i>		
Bank Loan	-	46,975
Other Borrowings	26,256	-
Hire Purchase Finance	17,689	36,896
Less: Unexpired HP Interest	(2,816)	(2,177)
<i>Unsecured liabilities</i>		
Other Borrowings	854,051	523,613
Total current borrowings	895,180	605,307

	30 June 2016	30 June 2015
Note	\$	\$
NON-CURRENT		
<i>Secured liabilities:</i>		
Hire Purchase Finance	21,649	-
Less: Unexpired HP Interest	(1,329)	-
	20,320	-
Total non-current borrowings	20,320	-

Assets purchased using hire purchase finance, have a total cost of \$66,866, and a net book value of \$26,079 as at 30 June 2016.

17. Shares to be issued – parent company and group

	30 June 2016	30 June 2015
	\$	\$
CURRENT		
Shares to be issued	-	16,329,879
	-	16,329,879

On 23 June 2015, the group completed the acquisition of Mobilespectra Pty Ltd, in exchange for 5,325,279 shares of Microskin PLC, valued at \$16,329,879. These shares were approved for issue by a general meeting of the Company held 21 July 2015. At that time, this liability was extinguished.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

18. Issued capital – parent company and group

	30 June 2016	30 June 2015 (as restated)
	\$	\$
30,916,641 (2015: 9,037,686) fully paid ordinary shares	5,333,488	13,425,955
112,990 (2015: 160,000) part paid ordinary shares	-	-
128,249,775 (2015: nil) fully paid B shares	20,545,269	-
1,016,910 nil paid B shares	-	-
Total	25,878,757	13,425,955

	\$	No.
<i>Movements in ordinary shares</i>		
At 1 July 2015	13,425,955	9,037,686
Issue of shares to acquire Mobilespectra Pty Ltd (note 17)	9,402,124	5,325,279
Share split (issue 9 new B shares for every 1 Ordinary share)	(20,545,268)	-
Other issue of shares	3,050,677	16,666,666
At 30 June 2016	5,333,488	31,029,631

	\$	No.
<i>Movements in B shares</i>		
At 1 July 2015	-	-
10:1 Share split	20,545,269	129,266,685
At 30 June 2016	20,545,269	129,266,685

On creation of the B shares, the existing value of the share capital was split evenly between the existing Ordinary shares and the new B shares, with each Ordinary share held receiving an additional 9 B shares.

The holder of the ordinary shares is entitled to one vote per share at any meeting of the Company whether in person or by proxy. The holder is entitled to receive dividends declared from available profits and to the surplus of assets on a winding up.

The holder of B shares is conferred the same rights as a holder of ordinary shares, except that they are not entitled to dividends for 24 months following issue.

	\$
<i>Movements in Share premium</i>	
At 1 July 2015 [as restated]	233,101
Issue of shares to acquire Mobilespectra Pty Ltd (note 17)	7,051,593
At 30 June 2016	7,284,694

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

19. Reserves - group

The following are components of reserves of the Group, as at 30 June 2016:

	30 June 2016	30 June 2015
Note	\$	\$
Merger reserve	(11,397,975)	(11,397,975)
Foreign exchange reserve	(88,211)	31,802
	<u>(11,486,186)</u>	<u>(11,366,173)</u>

a) *Merger Reserve*

The merger reserve was created on acquisition of Microskin Holdings Limited by Microskin PLC, via a share for share exchange.

This balance reflects the increased value of equity created when the PLC was established, with share capital totalling \$13,122,223, vs the original share capital of Microskin Holdings Limited of \$1,704,248. It does not reflect any trading transactions that have been undertaken by the business.

b) *Foreign Exchange Reserve*

The foreign exchange reserve arises from the translation of foreign denominated subsidiaries into Australian Dollars, for presentation in these financial statements.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

20. Cash flow information

Reconciliation of result for the year to cashflows from operating activities

Reconciliation of net income to net cash provided by operating activities:

	Year ended 30 June 2016	Year ended 30 June 2015
	\$	\$
Profit/(loss) after income tax	(449,626)	3,660
Non-cash flows in profit:		
- amortisation/depreciation	34,111	33,633
- bad debts	4,846	-
Changes in assets and liabilities, net of the effects of purchase and disposal of subsidiaries:		
- (increase)in trade and other receivables	(51,447)	(225,214)
- decrease/(increase) in other assets	3,839	(1,054)
- (increase)/decrease in inventories	(43,931)	13,608
- (increase)/decrease in current tax receivable	-	2,586
- increase/(decrease) in trade and other payables	232,610	(307,806)
- increase in provisions	1,090	4,788
- effect of foreign exchange	(1,020)	-
Cashflow from operations	<u>(269,528)</u>	<u>(475,799)</u>

Non-cash transactions

There were no major non-cash transactions undertaken during the year.

21. Investment in subsidiary – parent company

Microskin PLC acquired control of Microskin Holdings Limited via a share for share exchange in 2013. The value of that acquisition was \$13,122,223. This was based on expected future earnings potential. At 30 June 2015, however, the net liabilities of the subsidiary were \$692,751. Thus, a provision was made against the value for the parent company, which shows in accumulated losses in their statement of financial position.

Please note, provisions are reversible in future years, depending on results and growth.

	30 June 2016	30 June 2015
	\$	\$
Value of shares held	13,122,223	13,122,223
Provision for impairment	(13,122,223)	(13,122,223)
Balance at year end date	<u>-</u>	<u>-</u>

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

22. Controlled entities

	Country of Incorporation	Percentage Owned (%) 30 June 2016	Percentage Owned (%) 30 June 2015
Subsidiaries of Microskin PLC:			
Microskin Holdings Pty Ltd	Australia	100	100
Microskin International Pty Ltd	Australia	100	100
Blonde Holdings Pty Ltd	Australia	100	100
Microskin Australia Pty Ltd	Australia	100	100
Microskin US LLC	USA	100	100
Microskin UK Limited	UK	100	100
Mobilespectra Pty Ltd	Australia	100	100

Acquisition of Mobilespectra Pty Ltd

On 23 June 2015, the Group completed an agreement to acquire Mobilespectra Pty Ltd, an Australian company. The acquisition terms provided for the issue of 5,325,279 shares in Microskin PLC, valued at \$16,329,879, in exchange for 100% of the share capital of Mobilespectra Pty Ltd.

Because Mobilespectra Pty Ltd was an asset holding company, and did not qualify as business – having a trade – the acquisition was accounted for as an asset acquisition, and the entire cost of acquisition was attributed to the asset acquired – the colour-matching app which forms a key part of the business' strategy for the coming years. See Note 14 for further detail.

23. Events after the end of the Reporting Period

In November 2016, the Group commenced negotiations to acquire Isocol International Limited, a specialist international distributor and holder of the international rights (outside Australia) to the popular Australian product "Isocol." The Directors expect this acquisition to be completed in December 2016.

Aside from as above disclosed, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

24. Related party transactions

Transactions during the year

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

	Year ended 30 June 2016	Year ended 30 June 2015
	\$	\$
Expenses paid by Microskin Holdings Ltd, on behalf of Microskin PLC	8,508	10,116
<i>Key Management Personnel (of the Group)</i> (Debt forgiveness from)/Consultant fees due to Zeehe Pty Ltd as trustee of the Amor Family Trust in which one of the directors has a beneficial interest	137,400	(243,031)
Settlement of liabilities to Skiptrak Pty Ltd (a company controlled by Mr Amor) via share issue	-	536,833

Balances at the year end date

	30 June 2016	30 June 2015
	\$	\$
<i>Key Management Personnel (of the Group)</i> Amounts due to Zeehe Pty Ltd as trustee of the Amor Family Trust in which one of the directors has a beneficial interest.	137,400	-
Amounts due to Mr Barry Lowndes	128,739	128,739
Amounts due to Mr Barry Amor	551,509	147,857
Amounts due to Mr Scott McTaggart	-	-
Amounts due to Mr David Merson	-	-

Parent Company

There have been no related party transactions made by Microskin PLC during the financial year. All balances and transactions disclosed above relate to subsidiaries of Microskin PLC.

Ultimate controlling party

Microskin PLC is majority owned by the directors, Mr Barry Amor and Mr Barry Lowndes. Together, they control 59% of the company's shares, through personal beneficial holdings and immediate family.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

25. Parent Information

Guarantees

Microskin PLC has not entered into any guarantees, in the financial period, in relation of the debts of its subsidiary.

Contingent Liabilities

At 30 June 2016, Microskin PLC did not have any contingent liabilities.

Contractual Commitments

At 30 June 2016, Microskin PLC had not entered into any contractual commitments for the acquisition of property, plant or equipment.

26. Financial Risk Management

The group's financial instruments consist mainly of deposits with banks, local money market instruments, short-term investments, accounts receivable and payable, loans to and from subsidiaries and leases.

The totals for each category of financial instruments, measured in accordance with IAS 39 as detailed in the accounting policies to these financial statements, are as follows:

	30 June 2016	30 June 2015
	\$	\$
Financial Assets		
Cash and cash equivalents	16,933	6,388
Trade and other receivables	422,632	371,185
Total financial assets	439,565	377,573
Financial Liabilities		
Financial liabilities at amortised cost		
Trade and other payables	642,472	408,772
Borrowings	915,500	605,307
Total financial liabilities	1,557,972	958,372

Financial risk management policies

The Board of Directors has overall responsibility for the establishment of the Group's financial risk management framework. This includes the development of policies covering specific areas such as foreign exchange risk, interest rate risk, credit risk and the use of derivatives.

Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities.

The day-to-day risk management is carried out by Microskin PLC's finance function under policies and objectives which have been approved by the Board of Directors. The Managing Director, Mr Amor, has been delegated the authority for designing and implementing processes which follow the objectives and policies. This includes monitoring the levels of exposure to interest rate and foreign exchange rate risk and assessment of market forecasts for interest rate and foreign exchange movements.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

The Board of Directors receives monthly reports which provide details of the effectiveness of the processes and policies in place.

The Group does not actively engage in the trading of financial assets for speculative purposes nor does it write options.

Mitigation strategies for specific risks faced are described below:

Credit risk

Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the Group and arises principally from the Group's trade and other receivables.

To mitigate this risk, the Group are working hand in hand with their franchise partners, and providing them with every assistance to help grow each individual franchisee.

Liquidity & cash flow risk

The group manages liquidity and cash flow risk by monitoring forecast cash flows and ensuring that adequate unutilised borrowing facilities are maintained. This is a focus area for the Board, due to the liquidity requirements of a trading business that holds inventory. The group's forecasting processes takes into account debt financing arrangements, future expected receipts, future expected payments, and investments required as part of the day to day operation of the business.

Market risk

Interest rate risk:

The group's external debt bank loan is variable rate and the chattel mortgage is fixed rate interest.

Foreign exchange risk:

Exposure to foreign exchange risk may result in the fair value or future cash flows of a financial instrument fluctuating due to movement in foreign exchange rates of currencies in which the Group holds financial instruments which are other than the AUD functional currency of the Group.

Price risk

The group is not exposed to any material commodity price risk, or securities price risk.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

27. Commitments and contingencies

At 30 June 2016 the Group did not have any contingencies.

At 30 June 2016 the Group had the following obligations under non-cancellable finance leases:

	30 June 2016	30 June 2015
	\$	\$
Finance lease commitments		
Payable – minimum lease payments		
- Not later than 12 months	17,689	36,896
- Between 12 months and 5 years	21,649	-
Minimum lease payments	39,338	36,896
(Less future finance charges)	(4,145)	(2,177)
Present value of minimum lease payments	35,193	34,719

28. Share based payments

During the year, the company engaged in the following transactions via issue of shares:

<i>Transaction</i>	<i>Number of shares issued</i>	<i>Value of shares issued</i>
Acquisition of Mobilespectra Pty Ltd	5,325,279	16,329,879
Amaline Drawdown	16,666,666	3,050,678

Other than as above disclosed, no shares were granted to suppliers as shared based payments during this or the preceding financial period. No share options have been granted to employees or directors.

MICROSKIN PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

29. Company details

The registered office of the company is:

Microskin PLC
27 Old Gloucester Street
London
United Kingdom
WC1N 3AX

The principal place of business is:

Microskin Holdings Pty Ltd
271a Rode Road
Wavell Heights QLD 4012
Australia